Published in Future Neurol on November 01, 2012
ALS as a distal axonopathy: molecular mechanisms affecting neuromuscular junction stability in the presymptomatic stages of the disease. Front Neurosci (2014) 1.10
ROCK2 is a major regulator of axonal degeneration, neuronal death and axonal regeneration in the CNS. Cell Death Dis (2014) 1.08
Cytoskeletal regulation dominates temperature-sensitive proteomic changes of hibernation in forebrain of 13-lined ground squirrels. PLoS One (2013) 0.88
Moving towards effective therapeutic strategies for Neuronal Ceroid Lipofuscinosis. Orphanet J Rare Dis (2016) 0.88
Collapsin response mediator protein 2 (CRMP2) interacts with N-methyl-D-aspartate (NMDA) receptor and Na+/Ca2+ exchanger and regulates their functional activity. J Biol Chem (2014) 0.87
Novel monoclonal antibodies to study tissue regeneration in planarians. BMC Dev Biol (2015) 0.84
Neuronal deletion of GSK3β increases microtubule speed in the growth cone and enhances axon regeneration via CRMP-2 and independently of MAP1B and CLASP2. BMC Biol (2014) 0.84
CRMP2 protein SUMOylation modulates NaV1.7 channel trafficking. J Biol Chem (2013) 0.83
SUMOylation alters CRMP2 regulation of calcium influx in sensory neurons. Channels (Austin) (2013) 0.82
Redox regulation of autophagy in healthy brain and neurodegeneration. Neurobiol Dis (2015) 0.82
A cell-penetrating ester of the neural metabolite lanthionine ketimine stimulates autophagy through the mTORC1 pathway: Evidence for a mechanism of action with pharmacological implications for neurodegenerative pathologies. Neurobiol Dis (2015) 0.81
Alternative functions of the brain transsulfuration pathway represent an underappreciated aspect of brain redox biochemistry with significant potential for therapeutic engagement. Free Radic Biol Med (2014) 0.81
Calpain-mediated cleavage of collapsin response mediator protein-2 drives acute axonal degeneration. Sci Rep (2016) 0.80
Specific binding of lacosamide to collapsin response mediator protein 2 (CRMP2) and direct impairment of its canonical function: implications for the therapeutic potential of lacosamide. Mol Neurobiol (2014) 0.79
Synaptoproteomic analysis of a rat gene-environment model of depression reveals involvement of energy metabolism and cellular remodeling pathways. Int J Neuropsychopharmacol (2014) 0.78
The functionalized amino acid (S)-Lacosamide subverts CRMP2-mediated tubulin polymerization to prevent constitutive and activity-dependent increase in neurite outgrowth. Front Cell Neurosci (2014) 0.78
Collapsin Response Mediator Protein-2 (CRMP2) is a Plausible Etiological Factor and Potential Therapeutic Target in Alzheimer's Disease: Comparison and Contrast with Microtubule-Associated Protein Tau. J Alzheimers Dis (2016) 0.77
Association between DPYSL2 gene polymorphisms and alcohol dependence in Caucasian samples. J Neural Transm (Vienna) (2013) 0.76
Increased phosphorylation of collapsin response mediator protein-2 at Thr514 correlates with β-amyloid burden and synaptic deficits in Lewy body dementias. Mol Brain (2016) 0.75
Estrogen deficiency is associated with hippocampal morphological remodeling of early postmenopausal mice. Oncotarget (2017) 0.75
Neuronal networks in mental diseases and neuropathic pain: Beyond brain derived neurotrophic factor and collapsin response mediator proteins. World J Psychiatry (2016) 0.75
Sustained relief of ongoing experimental neuropathic pain by a CRMP2 peptide aptamer with low abuse potential. Pain (2016) 0.75
CRMPs Function in Neurons and Glial Cells: Potential Therapeutic Targets for Neurodegenerative Diseases and CNS Injury. Mol Neurobiol (2016) 0.75
Prions. Proc Natl Acad Sci U S A (1998) 27.80
Alzheimer's disease: genes, proteins, and therapy. Physiol Rev (2001) 19.19
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol (2003) 14.87
Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science (2003) 6.35
Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol (2004) 6.26
Rapid induction of Alzheimer A beta amyloid formation by zinc. Science (1994) 5.34
Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res (2008) 5.29
The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell (1990) 5.24
GSK-3beta regulates phosphorylation of CRMP-2 and neuronal polarity. Cell (2005) 4.42
Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem (2005) 4.23
Axonal guidance mutants of Caenorhabditis elegans identified by filling sensory neurons with fluorescein dyes. Dev Biol (1985) 3.98
The etiologic classification of epilepsy. Epilepsia (2011) 3.88
Plexin-neuropilin-1 complexes form functional semaphorin-3A receptors. Cell (1999) 3.84
Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med (1997) 3.74
CRMP-2 binds to tubulin heterodimers to promote microtubule assembly. Nat Cell Biol (2002) 3.71
Calcium channel regulation and presynaptic plasticity. Neuron (2008) 3.28
Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios. Am J Hum Genet (2005) 3.03
Collapsin-induced growth cone collapse mediated by an intracellular protein related to UNC-33. Nature (1995) 2.78
CRMP-2 induces axons in cultured hippocampal neurons. Nat Neurosci (2001) 2.70
Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. Epilepsia (2001) 2.63
Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med (2001) 2.63
Kufs disease, the major adult form of neuronal ceroid lipofuscinosis, caused by mutations in CLN6. Am J Hum Genet (2011) 2.49
Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J Biol Chem (2004) 2.46
Conditional deletion of TrkB but not BDNF prevents epileptogenesis in the kindling model. Neuron (2004) 2.38
Neuronal ceroid lipofuscinoses. Biochim Biophys Acta (2008) 2.29
APP processing is regulated by cytoplasmic phosphorylation. J Cell Biol (2003) 2.21
Suppression of inflammatory and neuropathic pain by uncoupling CRMP-2 from the presynaptic Ca²⁺ channel complex. Nat Med (2011) 2.11
Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol Med (2002) 2.10
Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic Biol Med (2007) 2.08
Unmasking recurrent excitation generated by mossy fiber sprouting in the epileptic dentate gyrus: an emergent property of a complex system. Prog Brain Res (2007) 2.04
The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol (2007) 1.97
NMDA di-heteromeric receptor populations and associated proteins in rat hippocampus. J Neurosci (2007) 1.95
GSK-3 phosphorylation of the Alzheimer epitope within collapsin response mediator proteins regulates axon elongation in primary neurons. J Biol Chem (2004) 1.91
Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci U S A (1994) 1.91
Examination of the current top candidate genes for AD in a genome-wide association study. Mol Psychiatry (2009) 1.89
Semaphorin3A signalling is mediated via sequential Cdk5 and GSK3beta phosphorylation of CRMP2: implication of common phosphorylating mechanism underlying axon guidance and Alzheimer's disease. Genes Cells (2005) 1.86
CRMP-2 regulates polarized Numb-mediated endocytosis for axon growth. Nat Cell Biol (2003) 1.80
The recurrent mossy fiber pathway of the epileptic brain. Neurochem Res (2003) 1.80
Tubulin and CRMP-2 complex is transported via Kinesin-1. J Neurochem (2005) 1.80
Lesion-induced axonal sprouting and hyperexcitability in the hippocampus in vitro: implications for the genesis of posttraumatic epilepsy. Nat Med (1997) 1.79
Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid beta-peptide (1-42) in a transgenic Caenorhabditis elegans model. Neurobiol Aging (2003) 1.78
Axonal transport defects: a common theme in neurodegenerative diseases. Acta Neuropathol (2005) 1.76
Phosphorylation of collapsin response mediator protein-2 by Rho-kinase. Evidence for two separate signaling pathways for growth cone collapse. J Biol Chem (2000) 1.73
Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J Neurochem (2002) 1.73
Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium. Mol Psychiatry (2000) 1.71
A novel CDK5-dependent pathway for regulating GSK3 activity and kinesin-driven motility in neurons. EMBO J (2004) 1.71
Genome-wide association studies in Alzheimer's disease. Hum Mol Genet (2009) 1.70
Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J Struct Biol (2000) 1.69
Deficits in axonal transport precede ALS symptoms in vivo. Proc Natl Acad Sci U S A (2010) 1.66
Alpha2-chimaerin, cyclin-dependent Kinase 5/p35, and its target collapsin response mediator protein-2 are essential components in semaphorin 3A-induced growth-cone collapse. J Neurosci (2004) 1.66
CRMP-2 is involved in kinesin-1-dependent transport of the Sra-1/WAVE1 complex and axon formation. Mol Cell Biol (2005) 1.64
Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiol Dis (2005) 1.58
Phosphorylation by Rho kinase regulates CRMP-2 activity in growth cones. Mol Cell Biol (2005) 1.56
TOAD-64, a gene expressed early in neuronal differentiation in the rat, is related to unc-33, a C. elegans gene involved in axon outgrowth. J Neurosci (1995) 1.55
A molecular switch in amyloid assembly: Met35 and amyloid beta-protein oligomerization. J Am Chem Soc (2003) 1.55
Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. Neurobiol Aging (2005) 1.52
An atypical role for collapsin response mediator protein 2 (CRMP-2) in neurotransmitter release via interaction with presynaptic voltage-gated calcium channels. J Biol Chem (2009) 1.51
The role of neurotrophins in axonal growth, guidance, and regeneration. Curr Neurovasc Res (2007) 1.50
Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J Biol Chem (2001) 1.49
A novel gene family defined by human dihydropyrimidinase and three related proteins with differential tissue distribution. Gene (1996) 1.48
Neuron-specific phosphorylation of Alzheimer's beta-amyloid precursor protein by cyclin-dependent kinase 5. J Neurochem (2000) 1.48
Collapsin response mediator proteins (CRMPs): involvement in nervous system development and adult neurodegenerative disorders. Mol Neurobiol (2003) 1.47
Anterograde transport of TrkB in axons is mediated by direct interaction with Slp1 and Rab27. Dev Cell (2009) 1.45
Molecular and cellular basis of epileptogenesis in symptomatic epilepsy. Epilepsy Behav (2008) 1.44
The CRMP family of proteins and their role in Sema3A signaling. Adv Exp Med Biol (2007) 1.43
ZNRF1 promotes Wallerian degeneration by degrading AKT to induce GSK3B-dependent CRMP2 phosphorylation. Nat Cell Biol (2011) 1.39
Neurofibrillary tangle-associated collapsin response mediator protein-2 (CRMP-2) is highly phosphorylated on Thr-509, Ser-518, and Ser-522. Biochemistry (2000) 1.39
Methionine 35 oxidation reduces fibril assembly of the amyloid abeta-(1-42) peptide of Alzheimer's disease. J Biol Chem (2002) 1.39
Role of CRMP-2 in neuronal polarity. J Neurobiol (2004) 1.37
Biosynthesis and intracellular targeting of the CLN3 protein defective in Batten disease. Hum Mol Genet (1998) 1.37
Lacosamide. Neurotherapeutics (2007) 1.36
Ziconotide for treatment of severe chronic pain. Lancet (2010) 1.34
TUC-4b, a novel TUC family variant, regulates neurite outgrowth and associates with vesicles in the growth cone. J Neurosci (2003) 1.33
Collapsin response mediator protein-2: an emerging pathologic feature and therapeutic target for neurodisease indications. Mol Neurobiol (2011) 1.33
Brain CRMP forms heterotetramers similar to liver dihydropyrimidinase. J Neurochem (1997) 1.33
Distinct priming kinases contribute to differential regulation of collapsin response mediator proteins by glycogen synthase kinase-3 in vivo. J Biol Chem (2006) 1.33
Different mechanisms of oxidative stress and neurotoxicity for Alzheimer's A beta(1--42) and A beta(25--35). J Am Chem Soc (2001) 1.32
Molecular characterization of CRMP5, a novel member of the collapsin response mediator protein family. J Biol Chem (2000) 1.31
Identification of CRAM, a novel unc-33 gene family protein that associates with CRMP3 and protein-tyrosine kinase(s) in the developing rat brain. J Biol Chem (2000) 1.31
Targeting chronic and neuropathic pain: the N-type calcium channel comes of age. NeuroRx (2005) 1.29
Structural bases for CRMP function in plexin-dependent semaphorin3A signaling. EMBO J (2003) 1.29
Immunohistochemical evidence of seizure-induced activation of trk receptors in the mossy fiber pathway of adult rat hippocampus. J Neurosci (1999) 1.29
Cytosolic O-glycosylation is abundant in nerve terminals. J Neurochem (2001) 1.26
Calpain-mediated collapsin response mediator protein-1, -2, and -4 proteolysis after neurotoxic and traumatic brain injury. J Neurotrauma (2007) 1.26
Neuronal death and survival under oxidative stress in Alzheimer and Parkinson diseases. CNS Neurol Disord Drug Targets (2007) 1.24
WASP and SCAR/WAVE proteins: the drivers of actin assembly. J Cell Sci (2009) 1.23
Collapsin response mediator protein-2 is associated with neurofibrillary tangles in Alzheimer's disease. J Biol Chem (1998) 1.23
Early postmitotic neurons transiently express TOAD-64, a neural specific protein. J Comp Neurol (1995) 1.21
Neuronal ceroid lipofuscinosis (nclf), a new disorder of the mouse linked to chromosome 9. Am J Med Genet (1998) 1.21
Collapsin response mediator protein-2 hyperphosphorylation is an early event in Alzheimer's disease progression. J Neurochem (2007) 1.20
Regulation of N-type voltage-gated calcium channels (Cav2.2) and transmitter release by collapsin response mediator protein-2 (CRMP-2) in sensory neurons. J Cell Sci (2009) 1.17
On the relation of oxidative stress to neuroinflammation: lessons learned from the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. Antioxid Redox Signal (2006) 1.17
Therapeutic approaches to epileptogenesis--hope on the horizon. Epilepsia (2010) 1.16
Immunohistochemical evidence of seizure-induced activation of trkB receptors in the mossy fiber pathway of adult mouse hippocampus. J Neurosci (2002) 1.15
Upregulation of dihydropyrimidinase-related protein 2, spectrin alpha II chain, heat shock cognate protein 70 pseudogene 1 and tropomodulin 2 after focal cerebral ischemia in rats--a proteomics approach. Neurochem Int (2006) 1.15
Neuroprotection against traumatic brain injury by a peptide derived from the collapsin response mediator protein 2 (CRMP2). J Biol Chem (2011) 1.15
CaMKII phosphorylates collapsin response mediator protein 2 and modulates axonal damage during glutamate excitotoxicity. J Neurochem (2009) 1.14
Trolox and 17beta-estradiol protect against amyloid beta-peptide neurotoxicity by a mechanism that involves modulation of the Wnt signaling pathway. J Biol Chem (2005) 1.14
Cyclin-dependent kinase-5 in neurodegeneration. J Neurochem (2004) 1.14
Cellulose synthase-like CslF genes mediate the synthesis of cell wall (1,3;1,4)-beta-D-glucans. Science (2006) 3.11
Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice--a model of familial amyotrophic lateral sclerosis. Free Radic Biol Med (2005) 2.51
Suppression of inflammatory and neuropathic pain by uncoupling CRMP-2 from the presynaptic Ca²⁺ channel complex. Nat Med (2011) 2.11
Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic Biol Med (2007) 2.08
Oxidative stress in brain aging. Implications for therapeutics of neurodegenerative diseases. Neurobiol Aging (2002) 2.06
A barley cellulose synthase-like CSLH gene mediates (1,3;1,4)-beta-D-glucan synthesis in transgenic Arabidopsis. Proc Natl Acad Sci U S A (2009) 1.97
Antioxidants in central nervous system diseases: preclinical promise and translational challenges. J Alzheimers Dis (2008) 1.88
Oxidative stress in Alzheimer's disease brain: new insights from redox proteomics. Eur J Pharmacol (2006) 1.57
Biliverdin reductase-A: a novel drug target for atorvastatin in a dog pre-clinical model of Alzheimer disease. J Neurochem (2011) 1.53
Ad lib smoking in post-traumatic stress disorder: an electronic diary study. Nicotine Tob Res (2008) 1.45
Controlled enzymatic production of astrocytic hydrogen peroxide protects neurons from oxidative stress via an Nrf2-independent pathway. Proc Natl Acad Sci U S A (2010) 1.45
Mixed-linkage (1-->3),(1-->4)-beta-D-glucan is not unique to the Poales and is an abundant component of Equisetum arvense cell walls. Plant J (2008) 1.41
Redox proteomics identification of oxidatively modified brain proteins in Alzheimer's disease and mild cognitive impairment: insights into the progression of this dementing disorder. J Alzheimers Dis (2007) 1.40
Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. Neurobiol Dis (2008) 1.38
Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment. Neurosci Lett (2006) 1.38
Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease. Biochim Biophys Acta (2010) 1.38
Plant cell wall biosynthesis: genetic, biochemical and functional genomics approaches to the identification of key genes. Plant Biotechnol J (2006) 1.35
Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci (2006) 1.34
Lipopolysaccharide alters the blood-brain barrier transport of amyloid beta protein: a mechanism for inflammation in the progression of Alzheimer's disease. Brain Behav Immun (2009) 1.32
Proteomic identification of oxidized mitochondrial proteins following experimental traumatic brain injury. J Neurotrauma (2007) 1.30
Over-expression of specific HvCslF cellulose synthase-like genes in transgenic barley increases the levels of cell wall (1,3;1,4)-β-d-glucans and alters their fine structure. Plant Biotechnol J (2011) 1.30
Redox proteomics in selected neurodegenerative disorders: from its infancy to future applications. Antioxid Redox Signal (2012) 1.24
An increase in S-glutathionylated proteins in the Alzheimer's disease inferior parietal lobule, a proteomics approach. J Neurosci Res (2007) 1.23
Adriamycin-induced, TNF-alpha-mediated central nervous system toxicity. Neurobiol Dis (2006) 1.22
Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer's disease. Brain Res (2007) 1.21
A comparative review of cell culture systems for the study of microglial biology in Alzheimer's disease. J Neuroinflammation (2012) 1.21
Oxidatively modified autoantigens in autoimmune diseases. Free Radic Biol Med (2006) 1.20
Amyloid β-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression. Antioxid Redox Signal (2013) 1.20
In vivo oxidative stress in brain of Alzheimer disease transgenic mice: Requirement for methionine 35 in amyloid beta-peptide of APP. Free Radic Biol Med (2009) 1.20
Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer's disease. Antioxid Redox Signal (2006) 1.20
Regulation of N-type voltage-gated calcium channels (Cav2.2) and transmitter release by collapsin response mediator protein-2 (CRMP-2) in sensory neurons. J Cell Sci (2009) 1.17
Pin1 in Alzheimer's disease. J Neurochem (2006) 1.16
The arachidonic acid 5-lipoxygenase inhibitor nordihydroguaiaretic acid inhibits tumor necrosis factor alpha activation of microglia and extends survival of G93A-SOD1 transgenic mice. J Neurochem (2004) 1.15
Neuroprotection against traumatic brain injury by a peptide derived from the collapsin response mediator protein 2 (CRMP2). J Biol Chem (2011) 1.15
Merging Structural Motifs of Functionalized Amino Acids and α-Aminoamides Results in Novel Anticonvulsant Compounds with Significant Effects on Slow and Fast Inactivation of Voltage-gated Sodium Channels and in the Treatment of Neuropathic Pain. ACS Chem Neurosci (2011) 1.11
The transcriptional regulator LEUNIG_HOMOLOG regulates mucilage release from the Arabidopsis testa. Plant Physiol (2011) 1.11
Translational research involving oxidative stress and diseases of aging. Free Radic Biol Med (2011) 1.10
Free radical mediated oxidative stress and toxic side effects in brain induced by the anti cancer drug adriamycin: insight into chemobrain. Free Radic Res (2005) 1.10
Modification of lupus-associated 60-kDa Ro protein with the lipid oxidation product 4-hydroxy-2-nonenal increases antigenicity and facilitates epitope spreading. Free Radic Biol Med (2005) 1.09
Redox proteomics identification of 4-hydroxynonenal-modified brain proteins in Alzheimer's disease: Role of lipid peroxidation in Alzheimer's disease pathogenesis. Proteomics Clin Appl (2009) 1.08
Adriamycin-mediated nitration of manganese superoxide dismutase in the central nervous system: insight into the mechanism of chemobrain. J Neurochem (2007) 1.08
Proteomic identification of proteins oxidized by Abeta(1-42) in synaptosomes: implications for Alzheimer's disease. Brain Res (2005) 1.06
HIV-dementia, Tat-induced oxidative stress, and antioxidant therapeutic considerations. Brain Res Brain Res Rev (2005) 1.05
Antisense directed at the Abeta region of APP decreases brain oxidative markers in aged senescence accelerated mice. Brain Res (2004) 1.04
Alumina nanoparticles induce expression of endothelial cell adhesion molecules. Toxicol Lett (2008) 1.03
Proteomic analysis of 4-hydroxy-2-nonenal-modified proteins in G93A-SOD1 transgenic mice--a model of familial amyotrophic lateral sclerosis. Free Radic Biol Med (2005) 1.03
Identification of lanthionine synthase C-like protein-1 as a prominent glutathione binding protein expressed in the mammalian central nervous system. Biochemistry (2007) 1.03
Oxidative stress and neuroinflammation in Alzheimer's disease and amyotrophic lateral sclerosis: common links and potential therapeutic targets. J Alzheimers Dis (2004) 1.03
Nitrones as neuroprotectants and antiaging drugs. Ann N Y Acad Sci (2002) 1.03
Predictors of lapse in first week of smoking abstinence in PTSD and non-PTSD smokers. Nicotine Tob Res (2012) 1.03
Elevated levels of pro-apoptotic p53 and its oxidative modification by the lipid peroxidation product, HNE, in brain from subjects with amnestic mild cognitive impairment and Alzheimer's disease. J Cell Mol Med (2008) 1.03
Chemo brain (chemo fog) as a potential side effect of doxorubicin administration: role of cytokine-induced, oxidative/nitrosative stress in cognitive dysfunction. Adv Exp Med Biol (2010) 1.02
Development and characterization of novel derivatives of the antiepileptic drug lacosamide that exhibit far greater enhancement in slow inactivation of voltage-gated sodium channels. ACS Chem Neurosci (2011) 1.02
Oxidative damage in brain from human mutant APP/PS-1 double knock-in mice as a function of age. Free Radic Biol Med (2008) 1.02
Ethyl ferulate, a lipophilic polyphenol, induces HO-1 and protects rat neurons against oxidative stress. Antioxid Redox Signal (2004) 1.02
Loss of phospholipid asymmetry and elevated brain apoptotic protein levels in subjects with amnestic mild cognitive impairment and Alzheimer disease. Neurobiol Dis (2007) 1.01
Immuno-spin trapping of protein and DNA radicals: "tagging" free radicals to locate and understand the redox process. Free Radic Biol Med (2009) 1.01
Quantitative proteomics analysis of phosphorylated proteins in the hippocampus of Alzheimer's disease subjects. J Proteomics (2011) 1.01
Glutathione elevation by gamma-glutamyl cysteine ethyl ester as a potential therapeutic strategy for preventing oxidative stress in brain mediated by in vivo administration of adriamycin: Implication for chemobrain. J Neurosci Res (2007) 1.00
2-Mercaptoethane sulfonate prevents doxorubicin-induced plasma protein oxidation and TNF-α release: implications for the reactive oxygen species-mediated mechanisms of chemobrain. Free Radic Biol Med (2011) 1.00
Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis. Exp Neurol (2009) 0.99
A survey of sesamin and composition of tocopherol variability from seeds of eleven diverse sesame (Sesamum indicum L.) genotypes using HPLC-PAD-ECD. Phytochem Anal (2008) 0.99
Roles of 3-nitrotyrosine- and 4-hydroxynonenal-modified brain proteins in the progression and pathogenesis of Alzheimer's disease. Free Radic Res (2010) 0.98
Alteration of hepatic structure and oxidative stress induced by intravenous nanoceria. Toxicol Appl Pharmacol (2012) 0.98
In silico docking and electrophysiological characterization of lacosamide binding sites on collapsin response mediator protein-2 identifies a pocket important in modulating sodium channel slow inactivation. J Biol Chem (2010) 0.98
Proteomics-determined differences in the concanavalin-A-fractionated proteome of hippocampus and inferior parietal lobule in subjects with Alzheimer's disease and mild cognitive impairment: implications for progression of AD. J Proteome Res (2009) 0.96
Rodent Abeta(1-42) exhibits oxidative stress properties similar to those of human Abeta(1-42): Implications for proposed mechanisms of toxicity. J Alzheimers Dis (2004) 0.96
Atorvastatin treatment in a dog preclinical model of Alzheimer's disease leads to up-regulation of haem oxygenase-1 and is associated with reduced oxidative stress in brain. Int J Neuropsychopharmacol (2011) 0.96
Role of phenylalanine 20 in Alzheimer's amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity. Chem Res Toxicol (2004) 0.95
Brain distribution and toxicological evaluation of a systemically delivered engineered nanoscale ceria. Toxicol Sci (2010) 0.95
Heme oxygenase-1 posttranslational modifications in the brain of subjects with Alzheimer disease and mild cognitive impairment. Free Radic Biol Med (2012) 0.95
Oxidative modification to LDL receptor-related protein 1 in hippocampus from subjects with Alzheimer disease: implications for Aβ accumulation in AD brain. Free Radic Biol Med (2010) 0.95
Further insights into the antinociceptive potential of a peptide disrupting the N-type calcium channel-CRMP-2 signaling complex. Channels (Austin) (2011) 0.95
Identification of 3-nitrotyrosine-modified brain proteins by redox proteomics. Methods Enzymol (2008) 0.94
Structure of human lanthionine synthetase C-like protein 1 and its interaction with Eps8 and glutathione. Genes Dev (2009) 0.94
Anti-inflammatory effects of tocopherol metabolites. Biochem Biophys Res Commun (2004) 0.94
Inhibition of transmitter release and attenuation of anti-retroviral-associated and tibial nerve injury-related painful peripheral neuropathy by novel synthetic Ca2+ channel peptides. J Biol Chem (2012) 0.94
Targeting multiple conformations leads to small molecule inhibitors of the uPAR·uPA protein-protein interaction that block cancer cell invasion. ACS Chem Biol (2011) 0.94
Effects of oxidative and nitrosative stress in brain on p53 proapoptotic protein in amnestic mild cognitive impairment and Alzheimer disease. Free Radic Biol Med (2008) 0.93
Increase in Mrp1 expression and 4-hydroxy-2-nonenal adduction in heart tissue of Adriamycin-treated C57BL/6 mice. Mol Cancer Ther (2006) 0.93
Oxidative and nitrosative modifications of biliverdin reductase-A in the brain of subjects with Alzheimer's disease and amnestic mild cognitive impairment. J Alzheimers Dis (2011) 0.93
Emerging roles of collapsin response mediator proteins (CRMPs) as regulators of voltage-gated calcium channels and synaptic transmission. Commun Integr Biol (2010) 0.92
In vivo protective effects of ferulic acid ethyl ester against amyloid-beta peptide 1-42-induced oxidative stress. J Neurosci Res (2006) 0.92
Distribution, elimination, and biopersistence to 90 days of a systemically introduced 30 nm ceria-engineered nanomaterial in rats. Toxicol Sci (2012) 0.91
Oxidative modification of lipoic acid by HNE in Alzheimer disease brain. Redox Biol (2013) 0.91
The nitration product 5-nitro-gamma-tocopherol is increased in the Alzheimer brain. Nitric Oxide (2002) 0.91
Glutathionylation of the pro-apoptotic protein p53 in Alzheimer's disease brain: implications for AD pathogenesis. Neurochem Res (2009) 0.91
Biliverdin reductase--a protein levels and activity in the brains of subjects with Alzheimer disease and mild cognitive impairment. Biochim Biophys Acta (2011) 0.90
Oxidative stress and toxicity induced by the nucleoside reverse transcriptase inhibitor (NRTI)--2',3'-dideoxycytidine (ddC): relevance to HIV-dementia. Exp Neurol (2006) 0.90
Low molecular weight thiol amides attenuate MAPK activity and protect primary neurons from Abeta(1-42) toxicity. Brain Res (2006) 0.90
Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: a novel mechanism of action. Pharmacol Res (2010) 0.90
Hyphal cell walls from the plant pathogen Rhynchosporium secalis contain (1,3/1,6)-beta-D-glucans, galacto- and rhamnomannans, (1,3;1,4)-beta-D-glucans and chitin. FEBS J (2009) 0.90
Reactive oxygen species in choline deficiency induced carcinogenesis and nitrone inhibition. Mol Cell Biochem (2002) 0.90